dc.contributor.author | Osterlund, Emerik | |
dc.contributor.author | Ristimäki, Ari | |
dc.contributor.author | Mäkinen, Markus J. | |
dc.contributor.author | Kytölä, Soili | |
dc.contributor.author | Kononen, Juha | |
dc.contributor.author | Pfeiffer, Per | |
dc.contributor.author | Soveri, Leena-Maija | |
dc.contributor.author | Keinänen, Mauri | |
dc.contributor.author | Sorbye, Halfdan | |
dc.contributor.author | Nunes, Luís | |
dc.contributor.author | Salminen, Tapio | |
dc.contributor.author | Nieminen, Lasse | |
dc.contributor.author | Uutela, Aki | |
dc.contributor.author | Halonen, Päivi | |
dc.contributor.author | Ålgars, Annika | |
dc.contributor.author | Sundström, Jari | |
dc.contributor.author | Kallio, Raija | |
dc.contributor.author | Ristamäki, Raija | |
dc.contributor.author | Lamminmäki, Annamarja | |
dc.contributor.author | Stedt, Hanna | |
dc.contributor.author | Heervä, Eetu | |
dc.contributor.author | Kuopio, Teijo | |
dc.contributor.author | Sjöblom, Tobias | |
dc.contributor.author | Isoniemi, Helena | |
dc.contributor.author | Glimelius, Bengt | |
dc.contributor.author | Osterlund, Pia | |
dc.date.accessioned | 2024-04-08T12:12:26Z | |
dc.date.available | 2024-04-08T12:12:26Z | |
dc.date.created | 2023-10-11T15:28:53Z | |
dc.date.issued | 2023 | |
dc.identifier.issn | 0020-7136 | |
dc.identifier.uri | https://hdl.handle.net/11250/3125302 | |
dc.description.abstract | BRAF-V600E mutation (mt) is a strong negative prognostic and predictive biomarker in metastatic colorectal cancer (mCRC). Non-V600Emt, designated atypical BRAFmt (aBRAFmt) are rare, and little is known about their frequency, co-mutations and prognostic and predictive role. These were compared between mutational groups of mCRC patients collected from three Nordic population-based or real-world cohorts. Pathology of aBRAFmt was studied. The study included 1449 mCRC patients with 51 (3%) aBRAFmt, 182 (13%) BRAF-V600Emt, 456 (31%) RAS&BRAF wild-type (wt) and 760 (52%) RASmt tumours. aBRAFmt were seen in 2% of real-world and 4% of population-based cohorts. Twenty-six different aBRAFmt were detected, 11 (22%) class 2 (serrated adenocarcinoma in 2/9 tested), 32 (64%) class 3 (serrated in 15/25) and 4 (8%) unclassified. aBRAFmt patients were predominantly male, had more rectal primaries, less peritoneal metastases, deficient mismatch repair in one (2%), and better survival after metastasectomy (89% 5-year overall survival [OS]-rate) compared with BRAF-V600Emt. aBRAFmt and BRAF-V600Emt had poorer performance status and received fewer treatment lines than RAS&BRAFwt and RASmt. OS among aBRAFmt (median 14.4 months) was longer than for BRAF-V600Emt (11.2 months), but shorter than for RAS&BRAFwt (30.5 months) and RASmt (23.4 months). Addition of bevacizumab trended for better OS for the aBRAFmt. Nine patients with aBRAFmt received cetuximab/panitumumab without response. aBRAFmt represents a distinct subgroup differing from other RAS/BRAF groups, with serrated adenocarcinoma in only half. OS for patients with aBRAFmt tumours was slightly better than for BRAF-V600Emt, but worse than for RASmt and RAS&BRAFwt. aBRAFmt should not be a contraindication for metastasectomy. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Wiley | en_US |
dc.rights | Navngivelse-Ikkekommersiell 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/deed.no | * |
dc.title | Atypical (non-V600E) BRAF mutations in metastatic colorectal cancer in population and real-world cohorts | en_US |
dc.type | Journal article | en_US |
dc.type | Peer reviewed | en_US |
dc.description.version | publishedVersion | en_US |
dc.rights.holder | Copyright 2023 The Author(s) | en_US |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 2 | |
dc.identifier.doi | 10.1002/ijc.34733 | |
dc.identifier.cristin | 2183832 | |
dc.source.journal | International Journal of Cancer | en_US |
dc.source.pagenumber | 488-503 | en_US |
dc.identifier.citation | International Journal of Cancer. 2023, 154 (3), 488-503. | en_US |
dc.source.volume | 154 | en_US |
dc.source.issue | 3 | en_US |